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Summary 
Human metapneumovirus (hMPV) is one of several important viruses associated with 
childhood acute lower respiratory infection (ALRI). However, there are currently no global 
burden estimates for ALRI associated with hMPV in children, and there are no licenced 
vaccines or drugs for hMPV infections. We estimated age–stratified global morbidity and 
mortality burden of hMPV–associated ALRI among children under five years using data on 
laboratory–confirmed hMPV burden from different geographic regions.  
Methods 
We performed a systematic review of hMPV burden studies published between 1 January 
2001 and 31 December 2019 and identified a further 40 high–quality unpublished studies. We 
assessed the risk of bias using a modified Newcastle–Ottawa Scale. Incidence rates, hospital 
admission rates, and in–hospital case–fatality ratios (hCFRs) of hMPV–associated ALRI 
(defined as ALRI with laboratory–confirmed hMPV) were analysed using a generalized 
linear mixed model. We applied incidence and hospital admission rates of hMPV–associated 
ALRI to population estimates to yield the morbidity burden estimates. We estimated hMPV–
associated ALRI in–hospital deaths by combining hospital admissions and hCFRs of hMPV–
associated ALRI. We estimated the overall hMPV–associated ALRI deaths (both in–hospital 
and out–hospital deaths) using the number of in–hospital deaths, population–based childhood 
pneumonia mortality, and care–seeking for child pneumonia. We also estimated hMPV–
attributable ALRI cases, hospital admissions, and deaths (ALRI burden that are causally 
attributable to hMPV) by combining hMPV–associated burden estimates and attributable 
fractions of hMPV in laboratory–confirmed hMPV cases and deaths.  
Findings 
We estimated in 2018 that hMPV could be detected in 14.2 million (UR 10.2–20.1) ALRI 
cases, 643,000 (UR 425,000–977,000) hospital admissions, 7,700 (UR 2,600–48,800) in–
hospital deaths, and 16,100 (UR 5,700–88,000) overall ALRI deaths among children under 
five years globally. Of these cases and deaths, an estimated 11.1 million (UR 8.0–15.7) ALRI 
cases, 502,000 (UR 332,000–762,000) ALRI hospital admissions, and 11,300 (UR 4,000–
61,600) ALRI deaths could be causally attributable to hMPV. hMPV–associated ALRI 
incidence rate in the community setting did not vary much by age strata, while about 58% of 
hospital admissions were in infants less than 12 months; 64% of in–hospital deaths occurred 
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in the first six months of life, of which 80% occurred in low– and lower–middle income 
countries.  
Interpretation 
Infants younger than one year have disproportionately high risks of severe hMPV infections 
across settings, similar to respiratory syncytial virus and influenza virus. Infants younger than 
6 months in low– and lower–middle income countries are at greater risk of death from 
hMPV–associated ALRI compared with other countries. Our mortality estimates, though 
likely to be conservative and underestimate the true hMPV mortality burden, demonstrate the 
importance of intervention strategies for infants across all settings, and warrant continued 
efforts to improve the outcome of hMPV–associated ALRI among young infants in low– and 
lower–middle income countries.  
Funding 
Bill & Melinda Gates Foundation
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Research in context 
Evidence before this study 
Human metapneumovirus (hMPV) is a common virus in children with ALRI. Two recent 
pooled analyses among different populations have shown that hMPV are identified in 6.1–
6.4% of ALRI among patients under 20 years of age. However, no global estimates of 
hMPV–associated ALRI burden in children under 5 years have been made. One of the 
challenges to estimating global hMPV burden is the paucity of data on incidence of hMPV 
infections in published population–based studies that demonstrate the impact of the virus in 
defined populations.  
Added value of this study 
Our analysis was based on data on laboratory–confirmed hMPV ALRI (hMPV–associated 
ALRI) morbidity and mortality burden. We incorporated 159 studies with data on hMPV–
associated ALRI community incidence rates, hospital admission rates, hospitalised proportion 
positives, and in–hospital case–fatality ratios, including 40 high quality unpublished studies 
that provided data stratified by narrow age groups in children under 5 years. 27% of the data 
were from low–income and lower middle–income countries. Our hMPV–associated ALRI 
burden estimates by different settings and narrow age groups revealed the subgroup 
populations most vulnerable to hMPV–associated ALRI morbidity and mortality, providing 
evidence regarding the target populations and settings for future intervention studies and 
informing intervention strategies. Since the presence of hMPV in the upper respiratory tract 
in children with ALRI does not indicate causation, we reported global burden of ALRI that 
are causally attributable to hMPV (hMPV–attributable ALRI burden), which could help 
understand the role of this virus in causing childhood ALRI. We estimated that hMPV could 
be identified in 11% of ALRI cases, 4–13% of ALRI hospital admissions, and 2% of ALRI 
deaths among children under 5 years globally. After accounting for the causal attribution of 
hMPV, we estimated that 8% of ALRI cases, 3–10% of ALRI hospital admissions, and 1% of 
ALRI mortality could be attributed to hMPV. About 58% of these hospital admissions 
occurred in the first year of life. About 64% of the in–hospital deaths occurred in infants 
younger than 6 months, including 80% occurring in low– and lower middle–income 
countries.  
Implications of all the available evidence 
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Our systematic review provides the first estimates of global hMPV–associated ALRI and 
hMPV–attributable ALRI morbidity and mortality in children under 5 years, by narrow age 
bands. Our results indicate that infants less than 1 year of age have increased risk of severe 
hMPV–associated ALRI compared with older children. Infants younger than 6 months, 
especially those in low– and lower middle–income countries, are at greater risk of death from 
hMPV–associated ALRI compared with other countries. These findings warrant continued 
efforts to develop targeted intervention strategies to protect infants from hMPV infections, 
and to improve the outcome of infants with hMPV–associated ALRI, especially in low– and 
lower–middle income countries. Such strategies could include, for example, specific antiviral 
therapeutics, monoclonal antibodies, or vaccination for children and/or their mothers during 
pregnancy.
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Introduction 1 
Acute lower respiratory infections (ALRI) are one of the leading causes of morbidity and 2 
mortality in children globally, accounting for 10% of mortality in children under five years in 3 
2017.1 Human metapneumovirus (hMPV), first identified in 2001, is an important virus 4 
causing ALRI in young children.2-5 Previous evidence indicates that almost all children have 5 
been infected with hMPV by the age of five, and with most severe infections occurring in 6 
infants.6-10. Available pooled analyses among different populations have focused on broad 7 
age groups, and have shown that hMPV is associated with 6.1–6.4% of hospitalised ALRI 8 
among patients under 20 years of age worldwide.11,12 Incidence and mortality of hMPV–9 
associated ALRI have only been available in a very limited number of published literature, 10 
especially for narrow age groups. There are no global or regional burden estimates for 11 
children under five years. 12 
Using the published and unpublished data on laboratory–confirmed (culture, 13 
immunofluorescence assay, or molecular test) hMPV morbidity and mortality, we sought to 14 
estimate the global and regional number of hMPV–associated ALRI cases, hospital 15 
admissions, and mortality by age strata in children under five years for 2018. Since the 16 
presence of hMPV in children’s upper respiratory tract does not imply causation, we 17 
estimated the global burden of ALRI that are attributable to hMPV by accounting for the 18 
causal attribution of hMPV.  19 
The estimates would provide evidence for the further development of targeted interventions 20 
and treatment. A live–attenuated recombinant hMPV vaccine has been evaluated in a recent 21 
phase I clinical trial, though the result showed that the vaccine was over–attenuated for 22 
children aged 6–59 months.13 Antivirals against hMPV infections and several other types of 23 
vaccines have been investigated, but have not reached clinical trials.14-16  24 
Methods 25 
Systematic review, definitions, and assessment of risk of bias 26 
We conducted a systematic review on hMPV–associated ALRI burden in children under five 27 
years (appendix pp 4–5). We searched Medline (Ovid), Embase (Ovid), Global Health (Ovid: 28 
1973 onwards), CINAHL, Web of Science, Global Health Library, three Chinese databases 29 
(CNKI, Wanfang and Chongqing VIP), and Google (for grey literature). No language or 30 
publication restrictions were applied, and three reviewers (XW, LCV and YL) screened the 31 
titles and abstracts for eligibility and extracted data independently. Disagreements were 32 
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resolved by discussion between the reviewers. We supplemented the data from published 33 
studies with additional high-quality unpublished data (from ongoing studies or re–analysis of 34 
previously published studies) using agreed standardised approaches and definitions within a 35 
collaborative network - the Respiratory Virus Global Epidemiology Network.17  36 
We included studies that were published between January 1, 2001, and December 31, 2019, 37 
and reported any of the following data for children under five years: community incidence 38 
rates of ALRI (i.e., clinical pneumonia according to 2005 WHO Integrated Management of 39 
Childhood Illnesses18) with laboratory–confirmed hMPV; hospital admission rates of ALRI 40 
(i.e., physician–confirmed diagnosis of ALRI) or ALRI with hypoxaemia with laboratory–41 
confirmed hMPV; proportions of hospitalised ALRI with laboratory–confirmed hMPV; in–42 
hospital case–fatality ratios (hCFRs) of ALRI with laboratory–confirmed hMPV. Details of 43 
case definitions are in appendix pp 2–3.19 44 
Studies had to use a clear case definition for specimen collection and testing, and studies that 45 
reported incidence and hospital admission rate data had to show data for at least one complete 46 
calendar year (or at least one full influenza season if in a temperate region). We included 47 
hCFR data for any length of study period. We included proportion positive data if they were 48 
for at least one full calendar year. We excluded studies: without a clear denominator 49 
population at risk (limited to those reporting incidence and hospital admission rate data); 50 
those in which hMPV was not the primary outcome; reporting modelled burden estimates; 51 
those in which hMPV infections were diagnosed based on serology alone; only including 52 
population subgroups with high–risk conditions.    53 
We used a modified Newcastle–Ottawa Scale to assess the risk of bias in seven domains, 54 
including study design, adjustment for health utilization, patient groups excluded, definition, 55 
sampling strategy, diagnostic testing, and hypoxaemia ascertainment (appendix pp 25–56 
26).19,20  57 
Statistical analysis 58 
Our approach to burden estimation, including main analyses and sensitivity analyses is 59 
summarised in appendix p14. We estimated hMPV–associated ALRI cases, hospital 60 
admissions, and in–hospital deaths using a strategy similar to our previous analysis.19 First, 61 
we  estimated incidence rates, hospital admission rates, and hCFRs of hMPV–associated 62 
ALRI using a generalized linear mixed model.21 For the incidence rate and hospital admission 63 
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rate, we scaled the population–at–risk for the level of testing per study where available before 64 
meta-analyses (appendix p 23).  65 
hMPV-associated ALRI morbidity burden estimation 66 
After meta-analyses, we chose Monte Carlo Simulation to estimate morbidity burden as it 67 
allows us to combine meta-estimates and population estimates (United Nations population 68 
estimates for 2018).22 The median value of 10,000 samples simulated from a log–normal 69 
distribution was used as the point burden estimate and the 2∙5th and 97∙5th percentiles as the 70 
95% uncertainty ranges (UR). We followed the same strategy to promote consistency with 71 
our previous studies; other methods (e.g., resampling observed data) may yield comparable 72 
estimates.23 In the main analysis, we reported estimates stratified by three non–overlapping 73 
age bands (0–5 months, 6–11 months, and 12–59 months) and by 2018 child mortality 74 
settings (low; high: using the median value of under–five mortality rate, 16.6 per 1,000 live 75 
births, as the cut–off point) for each outcome where available.24 Global results are calculated 76 
as the sum of age– and region–specific estimates. The numbers of cases and deaths were 77 
rounded to the nearest thousand and hundred, respectively. In the community setting, we 78 
reported the incidence rate for the overall age band (0–59 months) as data were insufficient to 79 
allow disaggregation by narrower age bands. To incorporate information from studies with 80 
data for other age bands (e.g., 0-11 months), we imputed the numbers of cases for 0-59 81 
months using a multiple imputation approach as was done previously (appendix pp 21–22).19 82 
hMPV–associated ALRI in-hospital deaths 83 
We estimated hMPV–associated ALRI in–hospital deaths by combining the estimates of 84 
hospital admissions and hCFRs of hMPV–associated ALRI.17,25 Similar to morbidity 85 
estimation, global estimates of mortality are calculated as the sum of the estimates by the 86 
three age groups and by child mortality settings.  87 
Overall hMPV–associated deaths 88 
Many child ALRI deaths occur outside hospitals, especially in resource-limited settings due 89 
to the poor care-seeking and / limited access to care. We estimated a ratio (“inflation factor”) 90 
of overall ALRI deaths to in–hospital ALRI deaths at eight sites in six high child mortality 91 
countries (Mozambique, Kenya, South Africa, Burkina Faso, and Ghana in sub–Saharan 92 
Africa, Bangladesh in South Asia),19,26-28 We calculated the median inflation factor which 93 
was extrapolated to other high child mortality countries, and combined with estimates of in–94 
hospital deaths to yield overall hMPV–associated ALRI mortality (appendix p15).17,25,29 We 95 
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assumed that hMPV prevalence was the same in ALRI deaths in community and in hospitals. 96 
For low child mortality settings, the reciprocal of the proportion of children with pneumonia 97 
symptoms who received care, measured in Multiple Indicator Cluster Surveys, Demographic 98 
and Health Surveys and other national surveys, was used as a proxy for inflation factor.30 99 
This measure is available in many countries and regions, and can thus help improve the 100 
generalisation. The median inflation factor was extrapolated to other low child mortality 101 
countries without data. Compared to approximating the inflation factor using non-specific 102 
ALRI mortality, in this approach we assumed that the case-fatality ratios for pneumonia in 103 
hospitalised and non-hospitalised cases were broadly similar.  104 
hMPV-attributable cases, hospital admissions, and deaths 105 
The presence of hMPV in the upper respiratory tract of a child with ALRI may not indicate a 106 
causal association between hMPV and ALRI. Thus, we estimated the ALRI burden causally 107 
attributable to hMPV (i.e., hMPV–attributable ALRI burden) by combining (1) the hMPV–108 
associated ALRI burden estimates and (2) the fraction of laboratory–confirmed hMPV ALRI 109 
cases or deaths that are attributable to hMPV – or, the attributable fraction of hMPV in 110 
hMPV–associated ALRI cases or deaths. For the attributable fraction for hMPV–associated 111 
ALRI cases, we used a median value of 78% as the input based on three multi–country 112 
studies.3-5 The attributable fraction of hMPV–associated ALRI deaths was calculated using 113 
the attributable fraction of hMPV–associated ALRI cases and the ratio between hCFRs of 114 
hMPV–positive ALRI and hMPV–negative ALRI. We assumed that hCFR of hMPV negative 115 
ALRI was equal to that for those tested positive but not attributable to hMPV (detailed 116 
formulas in appendix p17).  117 
Sensitivity analyses 118 
In sensitivity analyses for hMPV–associated ALRI morbidity and in–hospital deaths, we 119 
reported estimates by country development status according to UNICEF definitions and by 120 
World Bank income levels (low– and lower–middle income, upper–middle income, and 121 
high–income).32,33 We additionally estimated the range of hMPV–associated ALRI hospital 122 
admissions by combining the proportion positives of hMPV in ALRI hospital admissions and 123 
the recent estimates of all-cause ALRI hospital admissions among children under five 124 
years.34,35We estimated overall hMPV–associated ALRI deaths for high child mortality 125 
settings in a sensitivity analysis by applying the proportion positives of hMPV in ALRI 126 
deaths to the number of ALRI deaths in children under five years for 2017.1 The proportion 127 
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of hMPV positives in ALRI deaths was estimated using data from hospital-based studies in 128 
the systematic review.  129 
We estimated hMPV–attributable mortality for high child mortality settings in a sensitivity 130 
analysis by applying the proportion of hMPV–attributable ALRI deaths to the number of 131 
ALRI deaths in children under five years for 2017. The proportion of hMPV–attributable 132 
ALRI deaths was estimated using data for the period December 2016 to October 2019 from 133 
Child Health and Mortality Prevention Surveillance.36,37 Details are in appendix p18. We 134 
reported the estimates from the main analysis. Sensitivity results are available in the appendix 135 
(pp 8–13, 16, 19). Details of included studies are available in the appendix (pp 34– 53). All 136 
analyses were done in R version 3.5.2.38,39 This study was conducted and reported in 137 
accordance with the Guidelines for Accurate and Transparent Health Estimates Reporting 138 
(GATHER) recommendations (appendix pp 59).40 139 
Role of the funding source 140 
The funder of the study had no role in study design, data collection, data analysis, data 141 
interpretation, or writing of the report. XW and HN had full access to all the data in the study 142 
and HN had final responsibility for the decision to submit for publication.  143 
Results 144 
Figure 1 shows the study selection for the systematic review. Overall, we identified 159 145 
studies with data on hMPV–associated ALRI community incidence (10 studies), hospital 146 
admission rates (39 studies), hospitalised proportion positives (116 studies), and hCFRs (73 147 
studies). Of these studies, 40 were unpublished studies from the collaboration network and 148 
119 studies from published literature. By World Bank income level, 7 studies were from low–149 
income countries, 36 from lower–middle income countries, 67 from upper–middle income 150 
countries, and 49 from high–income countries. The number of studies by characteristics for 151 
each outcome are summarised in appendix (pp6–7).  152 
We identified 11 studies reporting the incidence of hMPV–associated ALRI. There were ten 153 
studies with data for 0–59 months after imputation, including six studies from high child 154 
mortality settings; five studies from lower–middle income countries, two studies from upper–155 
middle income countries, and three studies from high–income countries. Four studies 156 
reported the rates for the pre–2010 period. The hMPV–associated ALRI incidence rate meta–157 
estimate was 22.1 (95%CI 17.0–28.7) per 1,000 children per year for 0–59 months in high 158 
child mortality settings, and 18.9 (95%CI 11.2–31.9) for low child mortality settings. Thus, 159 
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we estimated 14.2 million (UR 10.2–20.1) hMPV–associated ALRI cases globally in children 160 
under five years (Table 1).  161 
 162 
We identified 39 studies reporting hMPV–associated ALRI hospital admission rates, 163 
including 29 studies reporting data by three narrow age bands (0–5 months, 6–11 months, or 164 
12–59 months). The hospital admission rate meta–estimate was more than 4–fold higher in 165 
infants aged 0–5 months and 6–11 months (2.2–3.3 per 1,000 children per year) than for 166 
children aged 12–59 months (0.3–0.6 per 1,000 children per year) across World Bank income 167 
levels and child mortality settings (Table 2). In the analysis stratified by child mortality 168 
settings, we estimated 643,000 (UR 425,000–977,000) hMPV–associated ALRI hospital 169 
admissions globally in children under five years.  170 
There were 14 studies reporting hospital admission rates for hMPV–associated ALRI with 171 
hypoxaemia by three age groups, including five studies were from low child mortality 172 
settings. In the analysis stratified by child mortality settings, we estimated 112,000 (UR 173 
29,000–522,000) hospital admissions for hMPV–associated ALRI with hypoxaemia in 174 
children aged 0–59 months globally, accounting for 17% (112,000/643,000) of the hMPV–175 
associated ALRI hospital admissions (Table 2).  176 
A total of 73 studies reported hCFRs for hMPV–associated ALRI in children under five 177 
years, including 28 studies with data stratified by three narrow age bands. Infants aged 0–5 178 
months from high child mortality settings and lower–middle income countries had highest 179 
hCFRs [4.5% (95%CI 2.3–8.6) for lower–middle income countries; 3.3% (95%CI 1.7–6.1) 180 
for the high child mortality setting]. The hCFRs were lower for children aged 6–11 months 181 
and 12–59 months and for high–income countries (0.5–1.1%), with wide confidence intervals 182 
(Table 3). Based on these meta–estimates, we estimated 7,700 (UR 2,600–48,800) hMPV–183 
associated ALRI in–hospital deaths in children under five years. About 64% of these deaths 184 
were in young infants aged 0–5 months (4,900/7,700), and 88% (6,800/7,700) occurred in 185 
countries with high child mortality.  186 
 187 
Across 28 countries or regions with low child mortality, 22% to 94% of children with 188 
pneumonia received care from a health provider. About 71% of the data were from the period 189 
between 2010 and 2014. Based on these data, we estimated the median inflation factor was 190 
1∙3 across regions or countries, and 1,100 (UR 100–28,800) overall hMPV–associated ALRI 191 
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deaths among children under five years for low child mortality settings. Of the eight sites 192 
with data on pneumonia mortality in high child mortality settings, five sites were from rural 193 
areas, and six from African countries. Six studies reported data from the period between 2010 194 
and 2016, and the remaining two studies reported data from 2008 onward. The inflation 195 
factor ranged from 1∙5 to 3∙5 across the eight sites, with a median value of 2∙2. Thus, we 196 
estimated 14,900 (UR 5,600–59,700) overall hMPV–associated ALRI deaths in high child 197 
mortality settings, and 16,100 (UR 5,700–88,000) deaths globally.  198 
   199 
Applying attributable fraction of hMPV to the above estimates reporting hMPV-associated 200 
burden, we estimated that 11.1 million (UR 8.0–15.7) ALRI cases and 502,000 (UR 332,000–201 
762,000) ALRI hospital admissions could be attributed to hMPV in children under five years 202 
(Table 4). We estimated that the ratio of case–fatality of hMPV–attributable ALRI to hMPV–203 
associated cases was 0.9, and the AF for hMPV–associated ALRI deaths was 70% (appendix 204 
p17–18). This suggested that 11,300 (UR 4,000–61,600) overall ALRI deaths could be 205 
attributed to hMPV, including 10,400 (UR 3,900–41,800) in high child mortality settings 206 
(Table 4).  207 
We conducted several sensitivity analyses to estimate hospital admissions, in–hospital deaths, 208 
and overall deaths of hMPV–associated ALRI, and deaths of hMPV–attributable ALRI. For 209 
global hMPV–associated ALRI hospital admissions, the estimates in children under five 210 
years ranged from 626,000 to 650,000 in analyses by different stratification groups 211 
(Appendix p9); the proportion–based approach yielded a broader range (e.g., from 282,000 to 212 
902,000) (Appendix p10). The point estimate of global in–hospital deaths ranged from 7,200 213 
to 9,100 in children under five years, and an estimated 78% of the global in–hospital deaths 214 
occurred in lower–middle income countries (7,200/9,100) based on the results by World 215 
Bank income level (appendix p11). We estimated 19,900 (UR 12,100–33,200) hMPV–216 
associated ALRI deaths and 9,900 (UR 2,600–39,300) hMPV–attributable ALRI deaths in 217 
children aged 1–59 months in high child mortality settings in sensitivity analyses (appendix 218 
p16; 19). 219 
Discussion 220 
We reported the first global hMPV–associated ALRI burden estimates among children under 221 
5 years, by narrow age bands. Our estimates suggest that hMPV are detected in 11% of ALRI 222 
cases, 4–13% of ALRI hospital admissions, and 2% of ALRI deaths among children under 223 
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five years globally.1,34,35 About 8% of ALRI cases, 3–10% of ALRI hospital admissions, and 224 
1% of ALRI mortality can be attributed to hMPV. The wide uncertainty ranges of the present 225 
burden estimates reflected differences across studies, arising from variation in hMPV 226 
epidemiology between populations and methodological differences, and paucity of data, 227 
especially mortality data.  228 
We demonstrated that as has been shown for RSV and influenza, the hMPV–associated ALRI 229 
hospital admission rate was much higher in infants, with about 58% of hospital admissions 230 
and 71% in–hospital deaths in children under five years occurring in the first year of life.17,19 231 
This could be due to the immaturity of infant’s immune system and decaying maternal 232 
antibodies over the first several months of life.41,42 The consistently high hMPV–associated 233 
ALRI hospital admission rate among infants across different settings highlights the 234 
importance of developing safe and effective maternal hMPV vaccines and vaccines for 235 
infants.  236 
Our hCFR estimates show that young infants aged 0–5 months are at an increased risk of 237 
hMPV–associated ALRI mortality. hCFR estimates for 0–5 months varied substantially 238 
across settings, possibly reflecting the differences in disease severity at admission and in the 239 
quality of hospital care. Increased disease severity at presentation could be related to the high 240 
prevalence of certain underlying conditions and delays in care–seeking.3,35 The CFR (overall 241 
and in–hospital) and overall mortality due to ALRI among children under five years 242 
substantially reduced in the past 15 years due to socioeconomic development, reduced 243 
prevalence of pneumonia risk factors, and increased use of interventions.35,43 However, there 244 
were very few hMPV–associated ALRI deaths (1–3 deaths) in multi–year studies, and we 245 
were unable to observe any trends in the hCFR of hMPV–associated ALRI. Using available 246 
age–stratified data prior to 2010 (eligible if part of a study was from pre–2010 when data 247 
could not be stratified by year), we estimated 9,600 (UR 2,300–51,200) hMPV–associated 248 
ALRI in–hospital deaths among children under five years for 2010 (appendix p12).   249 
For high child mortality settings, the inflation factor was based on limited data.17 Although 250 
the inflation factor was only applied to high child mortality countries, there may be bias due 251 
to limited generalisability and location specific characteristics (prevalence of hMPV in 252 
childhood ALRI deaths). Nevertheless, our reported estimates for high child mortality 253 
settings are conservative and could increase by approximately 30% (19,900) using an 254 
alternative estimation approach (appendix p16). For low child mortality settings, the inflation 255 
factor and overall mortality estimate is likely underestimated because the definition of “care–256 
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seeking” is broader than the definition of “in–hospital”: contact with primary care is included 257 
as “care–seeking” in surveys, but are not included in the “in–hospital mortality” estimates in 258 
the present analysis. The US vital statistics data show that about 40% of under–five ALRI 259 
deaths (ICD–10 J09–22; U04) occurred in outpatient or emergency departments during 2010–260 
2017.44 Additionally, this analysis was based on one further assumption that there is no 261 
difference in CFR for hospitalised and non-hospitalised pneumonia cases. The direction of 262 
bias related to this assumption could be complicated by the two–way association between 263 
disease severity and care–seeking: children with more severe symptoms are more likely to 264 
receive hospital care; on the other hand, supportive care in hospitals can reduce the risk of 265 
death, and lack of appropriate care or delays in care can lead to rapid deterioration.45-47 266 
Moreover, data on pneumonia care–seeking in high–income countries have not been available 267 
in published reports; extrapolation from other low child mortality countries to high–income 268 
countries might cause bias. The estimates of inflation factor could also be affected by 269 
accuracy of assessment and completeness of documentation for ALRI or pneumonia. For 270 
example, the diagnosis of (presumptive) pneumonia in the UNICEF dataset is based on 271 
caregivers’ report, thus may be inaccurate and affect the estimates of inflation factor.  272 
In addition to the above, several other limitations are noted. Very few data were identified in 273 
Europe and Latin America, which could have affected the generalisation of the estimates. 274 
Moreover, heterogeneity in the methodology (variations in precise case definitions, 275 
proportion of eligible ALRI cases tested for hMPV) existed across studies for each outcome 276 
and could have likely biased our estimates (appendix p7). We adjusted for levels of testing 277 
when estimating hospital admission rates by assuming that the proportion positivity for 278 
hMPV was the same in those tested and untested. However, we did not adjust for the under–279 
detection when estimating hCFRs. The hCFR of hMPV–associated ALRI and in–hospital 280 
mortality might be underestimated, as suggested by the higher hCFR in those tested 281 
compared to those untested (appendix p24). The incidence and hospital admission rates of 282 
hMPV–associated ALRI are unlikely to be affected by the accuracy of test methods as 92% 283 
of the studies used polymerase chain reaction to detect hMPV. In addition to potential biases 284 
as described above, we summed yearly data to ensure precision in the age–stratified analysis, 285 
but while doing this we did not account for the variation across years (appendix p20).  286 
Our results show that infants under one year old have disproportionately high risks of severe 287 
hMPV infections across settings. Infants aged 0–5 months in low– and lower middle–income 288 
countries are susceptible to increased risk of mortality from hMPV–associated ALRI 289 
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compared with other countries, accounting for nearly 8 of every 10 global deaths occurring in 290 
this age group. These estimates highlight the importance of interventions for infants. For 291 
low– and lower middle–income countries, continued efforts are needed to reduce hMPV–292 
associated ALRI mortality among young children, especially infants, in hospitals and 293 
communities through improving access to care and case management in hospitals. In light of 294 
the paucity of data at regional levels, these estimates should be viewed as preliminary 295 
estimates. In future, additional high–quality data on childhood hMPV–associated ALRI 296 
cases, hospital admissions, and mortality, especially age–stratified data, would help refine the 297 
estimates and track the trends of hMPV–associated ALRI morbidity and mortality. 298 
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